🔴 Aytu BioScience is trading 6.1% down in pre-market as Nasdaq and S&P 500 decline

Aytu BioScience is trading at $2.14, down 6.14%, alongside a risk-off pre-market, with the Nasdaq Composite down 0.93% and S&P 500 down 0.52%.

• No new company-specific announcement explaining the September 28 move surfaced in the search.
• Fiscal 2026 results were announced September 22: Q4 revenue was $16.1 million, up 6% year over year, and adjusted earnings beat estimates; those earlier results do not explain this morning’s drop.